CL2023001201A1 - Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados - Google Patents
Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuteradosInfo
- Publication number
- CL2023001201A1 CL2023001201A1 CL2023001201A CL2023001201A CL2023001201A1 CL 2023001201 A1 CL2023001201 A1 CL 2023001201A1 CL 2023001201 A CL2023001201 A CL 2023001201A CL 2023001201 A CL2023001201 A CL 2023001201A CL 2023001201 A1 CL2023001201 A1 CL 2023001201A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- hair loss
- deuterated
- regimens
- loss disorders
- Prior art date
Links
- 201000004384 Alopecia Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000024963 hair loss Diseases 0.000 title abstract 2
- 230000003676 hair loss Effects 0.000 title abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 abstract 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 abstract 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un método de tratamiento en un sujeto con trastornos de pérdida de cabello que se tratan de manera beneficiosa mediante la administración de un inhibidor de JAK1 y/o JAK2. El método comprende administrar al sujeto una cantidad eficaz del Compuesto (I): o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106790P | 2020-10-28 | 2020-10-28 | |
| US202163155637P | 2021-03-02 | 2021-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001201A1 true CL2023001201A1 (es) | 2023-11-17 |
Family
ID=78725692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001201A CL2023001201A1 (es) | 2020-10-28 | 2023-04-26 | Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230390292A1 (es) |
| EP (1) | EP4236956A1 (es) |
| JP (1) | JP2023553253A (es) |
| KR (1) | KR20230093504A (es) |
| AU (1) | AU2021372512A1 (es) |
| CA (1) | CA3196551A1 (es) |
| CL (1) | CL2023001201A1 (es) |
| CO (1) | CO2023006808A2 (es) |
| DO (1) | DOP2023000085A (es) |
| IL (1) | IL302401A (es) |
| MX (1) | MX2023005027A (es) |
| PE (1) | PE20231945A1 (es) |
| WO (1) | WO2022094133A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023215520A1 (en) * | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| ATE282428T1 (de) | 2001-05-03 | 2004-12-15 | Hoffmann La Roche | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat |
| KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
| PL1993360T3 (pl) | 2005-12-28 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu |
| JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| JP7145080B2 (ja) | 2016-05-04 | 2022-09-30 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化ｊａｋ阻害剤による脱毛障害の処置 |
| AU2020219797A1 (en) | 2019-02-06 | 2021-09-02 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
-
2021
- 2021-10-28 US US18/033,730 patent/US20230390292A1/en active Pending
- 2021-10-28 PE PE2023001507A patent/PE20231945A1/es unknown
- 2021-10-28 JP JP2023526173A patent/JP2023553253A/ja active Pending
- 2021-10-28 EP EP21811647.3A patent/EP4236956A1/en active Pending
- 2021-10-28 IL IL302401A patent/IL302401A/en unknown
- 2021-10-28 CA CA3196551A patent/CA3196551A1/en active Pending
- 2021-10-28 AU AU2021372512A patent/AU2021372512A1/en active Pending
- 2021-10-28 KR KR1020237017998A patent/KR20230093504A/ko unknown
- 2021-10-28 MX MX2023005027A patent/MX2023005027A/es unknown
- 2021-10-28 WO PCT/US2021/057123 patent/WO2022094133A1/en active Application Filing
-
2023
- 2023-04-26 CL CL2023001201A patent/CL2023001201A1/es unknown
- 2023-04-28 DO DO2023000085A patent/DOP2023000085A/es unknown
- 2023-05-25 CO CONC2023/0006808A patent/CO2023006808A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4236956A1 (en) | 2023-09-06 |
| CO2023006808A2 (es) | 2023-09-08 |
| KR20230093504A (ko) | 2023-06-27 |
| AU2021372512A1 (en) | 2023-06-22 |
| PE20231945A1 (es) | 2023-12-05 |
| JP2023553253A (ja) | 2023-12-21 |
| CA3196551A1 (en) | 2022-05-05 |
| IL302401A (en) | 2023-06-01 |
| WO2022094133A1 (en) | 2022-05-05 |
| MX2023005027A (es) | 2023-07-31 |
| US20230390292A1 (en) | 2023-12-07 |
| WO2022094133A9 (en) | 2023-05-19 |
| DOP2023000085A (es) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| CL2021001951A1 (es) | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los desordenes asociados a la edad. | |
| NO20052625L (no) | Preparater for transdermal oksybutyninterapi. | |
| CL2023001201A1 (es) | Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados | |
| ECSP055854A (es) | Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2023002324A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| CL2021002533A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| BR112022018115A2 (pt) | Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| AR127501A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| EA202192234A1 (ru) | Комбинированная терапия для применения в лечении рака | |
| AR128711A1 (es) | Métodos para tratar carcinoma microcítico de pulmón | |
| BR112022018948A2 (pt) | Métodos de tratamento de lesão pulmonar com inibidores de cgrp | |
| AR128870A1 (es) | Inhibidores de tyk2 y usos de los mismos | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| AR121415A1 (es) | INHIBIDORES DE LA QUINASA p38 QUE REDUCEN LA EXPRESIÓN DE DUX4 Y DE LOS GENES CORRIENTE ABAJO PARA USO EN EL TRATAMIENTO DE FSHD | |
| AR117120A1 (es) | Terapia de combinación que incluye un inhibidor de krasg¹²c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| AR114854A1 (es) | Métodos para el tratamiento del cáncer |